VEGFA and neoplasm: For example, in the phase III randomized GLOBE trial, VEGF inhibitor bevacizumab was combined with the VB-111 adenovirus, which delivers a transgene activating the Fas pro-apoptotic pathway in tumor endothelial cells; however, this combination did not extend mOS compared to bevacizumab monotherapy (Table 1) [85].